$2.34T
Total marketcap
$85.27B
Total volume
BTC 50.06%     ETH 15.38%
Dominance

C4 Therapeutics CCCC Stock

6.27 USD {{ price }} -0.870258% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
508.33M USD
LOW - HIGH [24H]
7.36 - 8.08 USD
VOLUME [24H]
109.91K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-2.67 USD

C4 Therapeutics Price Chart

C4 Therapeutics CCCC Financial and Trading Overview

C4 Therapeutics stock price 6.27 USD
Previous Close 3.57 USD
Open 3.57 USD
Bid 0 USD x 1100
Ask 0 USD x 1800
Day's Range 3.38 - 3.73 USD
52 Week Range 2.85 - 13.24 USD
Volume 453.06K USD
Avg. Volume 586.48K USD
Market Cap 177.12M USD
Beta (5Y Monthly) 2.097669
PE Ratio (TTM) N/A
EPS (TTM) -2.67 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 20 USD

CCCC Valuation Measures

Enterprise Value -9712373 USD
Trailing P/E N/A
Forward P/E -1.2237288
PEG Ratio (5 yr expected) -0.06
Price/Sales (ttm) 6.511537
Price/Book (mrq) 0.67464024
Enterprise Value/Revenue -0.357
Enterprise Value/EBITDA 0.073

Trading Information

C4 Therapeutics Stock Price History

Beta (5Y Monthly) 2.097669
52-Week Change -32.77%
S&P500 52-Week Change 20.43%
52 Week High 13.24 USD
52 Week Low 2.85 USD
50-Day Moving Average 3.28 USD
200-Day Moving Average 6.43 USD

CCCC Share Statistics

Avg. Volume (3 month) 586.48K USD
Avg. Daily Volume (10-Days) 619.24K USD
Shares Outstanding 49.06M
Float 42.52M
Short Ratio 4.99
% Held by Insiders 11.31%
% Held by Institutions 81.19%
Shares Short 3.25M
Short % of Float 11.27%
Short % of Shares Outstanding 6.61%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) -494.074%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -18.42%
Return on Equity (ttm) -41.89%

Income Statement

Revenue (ttm) 27.2M USD
Revenue Per Share (ttm) 0.56 USD
Quarterly Revenue Growth (yoy) -50.89%
Gross Profit (ttm) -86745000 USD
EBITDA -132477000 USD
Net Income Avi to Common (ttm) -131335000 USD
Diluted EPS (ttm) -2.54
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 270.32M USD
Total Cash Per Share (mrq) 5.51 USD
Total Debt (mrq) 85.46M USD
Total Debt/Equity (mrq) 32.56 USD
Current Ratio (mrq) 7.071
Book Value Per Share (mrq) 5.351

Cash Flow Statement

Operating Cash Flow (ttm) -112468000 USD
Levered Free Cash Flow (ttm) -69985000 USD

Profile of C4 Therapeutics

Country United States
State MA
City Watertown
Address 490 Arsenal Way
ZIP 02472
Phone 617 231 0700
Website https://www.c4therapeutics.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 146

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Q&A For C4 Therapeutics Stock

What is a current CCCC stock price?

C4 Therapeutics CCCC stock price today per share is 6.27 USD.

How to purchase C4 Therapeutics stock?

You can buy CCCC shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for C4 Therapeutics?

The stock symbol or ticker of C4 Therapeutics is CCCC.

Which industry does the C4 Therapeutics company belong to?

The C4 Therapeutics industry is Biotechnology.

How many shares does C4 Therapeutics have in circulation?

The max supply of C4 Therapeutics shares is 81.14M.

What is C4 Therapeutics Price to Earnings Ratio (PE Ratio)?

C4 Therapeutics PE Ratio is now.

What was C4 Therapeutics earnings per share over the trailing 12 months (TTM)?

C4 Therapeutics EPS is -2.67 USD over the trailing 12 months.

Which sector does the C4 Therapeutics company belong to?

The C4 Therapeutics sector is Healthcare.

C4 Therapeutics CCCC included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16175.09 USD
-1.62
3.94B USD 16125.33 USD 16341.46 USD 3.94B USD
NASDAQ Biotechnology NBI 4195.13 USD
-2.14
4174.1 USD 4266.29 USD
NASDAQ HealthCare IXHC 958.68 USD
-2.07
954.08 USD 972.42 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
NASDAQ Global Select Market Com NQGS 7876.03 USD
-1.61
7852.08 USD 7955.84 USD